×
About 3,685 results

ALLMedicine™ Hyperkalemia Center

Research & Reviews  1,052 results

Potassium content of the American food supply and implications for the management of hy...
https://doi.org/10.1111/sdi.13007
Seminars in Dialysis; Picard K, Picard C et. al.

Jul 30th, 2021 - Ultraprocessed foods can be a source of potassium additives. Excess potassium consumption can lead to hyperkalemia. How frequently potassium additives are found in the food supply and how they impact potassium content is not well documented. Using...

Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies.
https://doi.org/10.1007/s40265-021-01555-5 10.1001/archinte.160.16.2429 10.1016/j.jacc.2020.04.021 10.1016/j.ijcard.2017.07.035 10.1038/ki.1977.73 10.1152/advan.00121.2016 10.1152/ajpendo.00539.2015 10.1038/sj.ki.5002288 10.1016/j.semnephrol.2019.04.005 10.1038/ki.2015.243 10.1016/j.resuscitation.2015.07.017 10.1136/bmj.286.6372.1189 10.1001/archinte.158.8.917 10.1001/archinternmed.2009.132 10.7861/clinmedicine.15-3-239 10.1111/ijcp.13421 10.1186/s12882-018-1007-1 10.1016/j.nefro.2018.11.011 10.1161/HYPERTENSIONAHA.116.07363 10.1016/j.ekir.2020.11.021 10.1159/000508980 10.1016/S0140-6736(18)31694-5 10.1093/ndt/gfz174 10.1093/ckj/sfz129 10.2215/CJN.05850809 10.2215/CJN.01150112 10.1080/0886022X.2016.1216714 10.1186/s12882-019-1250-0 10.1159/000442393 10.1111/dme.13687 10.1093/eurheartj/suy028 10.1002/ejhf.1079 10.1093/ndt/gfx053 10.2215/CJN.04451206 10.1053/j.ajkd.2016.09.015 10.1007/s40620-014-0115-7 10.2215/CJN.00960112 10.1097/01.ASN.0000026611.07106.A7 10.2215/CJN.03880411 10.1053/j.ajkd.2010.03.022 10.1038/ki.2010.315 10.1159/000360094 10.1053/j.ajkd.2016.04.011 10.1016/S0002-9343(01)01068-3 10.1053/j.ajkd.2008.04.031 10.1038/sj.ki.5001657 10.1093/ndt/gft515 10.1111/j.1525-139X.2007.00367.x 10.1016/S0272-6386(96)90465-5 10.1159/000448341 10.1159/000502998 10.1093/ndt/gfp104 10.1053/j.ajkd.2016.10.024 10.1159/000437151 10.2215/CJN.01730215 10.1093/ndt/gfx312 10.1186/s12882-017-0710-7 10.1186/cc11872 10.1093/ndt/gfy249 10.1016/0002-8703(67)90174-3 10.1681/ASN.2016121344 10.1093/eurheartj/ehy100 10.1161/CIRCULATIONAHA.117.030576 10.1161/JAHA.120.017087 10.1097/00000441-197105000-00007 10.1097/00005792-198605000-00004 10.1681/ASN.V641134 10.1136/jcp.25.6.512 10.1016/j.nefro.2019.04.011 10.1172/JCI115544 10.1053/j.ajkd.2019.03.427 10.1186/s13613-019-0509-8 10.1056/NEJMra1503102 10.1007/s11154-016-9384-x 10.1016/0022-2828(95)90070-5 10.1053/j.ajkd.2017.09.003 10.1056/NEJMoa0801317 10.2215/CJN.07460713 10.1056/NEJM199604113341502 10.1016/S0140-6736(98)10363-X 10.1056/NEJMoa011161 10.1056/NEJMoa011303 10.1007/s00125-010-1922-6 10.1056/NEJMoa1208799 10.1056/NEJMoa1303154 10.1007/s40256-018-00321-5 10.1097/MAJ.0000000000000475 10.1016/j.amjmed.2020.03.037 10.2174/1381612825666190306162658 10.2174/1573402115666190415155512 10.1097/HJH.0000000000001940 10.1097/HJH.0000000000002187 10.1517/14740330903499257 10.1056/NEJM199909023411001 10.1056/NEJMoa040135 10.1053/j.ajkd.2007.10.040 10.1159/000237742 10.1002/cmdc.201200081 10.1007/164_2016_76 10.1001/jama.2015.10081 10.1016/j.jdiacomp.2016.11.021 10.1159/000503713 10.1056/NEJMoa2025845 10.1161/HYPERTENSIONAHA.117.10360 10.1681/ASN.2012111094 10.1159/000503712 10.2215/CJN.08960718 10.2215/CJN.02430312 10.1053/j.jrn.2016.02.005 10.2215/CJN.02830409 10.1001/archinte.158.1.26 10.1038/ki.2015.249 10.1093/ckj/sfaa198 10.1093/ckj/sfz070 10.1002/ejhf.2026 10.1056/NEJMoa1811744 10.1038/kisup.2012.73 10.1152/ajprenal.00343.2020 10.1053/j.ajkd.2019.07.016 10.1007/s40620-019-00656-5 10.1053/j.ajkd.2020.07.019 10.1124/jpet.120.000190 10.1016/S0140-6736(19)31388-1 10.1016/S0140-6736(18)32562-5 10.2215/CJN.07300717 10.1093/eurheartj/suy032 10.1161/HYPERTENSIONAHA.115.04889 10.1016/j.phrs.2016.07.032 10.1001/jama.2014.15688 10.1056/NEJMoa1410853 10.1001/jama.2015.7446 10.1159/000504078 10.2215/CJN.12651018 10.1093/ndt/gfz285 10.1093/eurheartj/ehq502 10.1016/S0140-6736(19)32135-X 10.1126/science.abf3363 10.1371/journal.pone.0186665 10.1001/jama.288.19.2421 10.1210/en.2004-0233 10.1056/NEJMoa1402686
Drugs Valdivielso JM, Balafa O et. al.

Jul 28th, 2021 - Despite recent therapeutic advances, chronic kidney disease (CKD) is one of the fastest growing global causes of death. This illustrates limitations of current therapeutic approaches and, potentially, unidentified knowledge gaps. For decades, reni...

Development and outcomes of hyperkalemia in hospitalized patients: potential implicatio...
https://doi.org/10.1016/j.ahj.2021.07.006
American Heart Journal; Wetmore JB, Yan H et. al.

Jul 23rd, 2021 - While severe hyperkalemia is commonly encountered, its manifestation in hospitalized patients and related outcomes are unclear. We aimed to examine development of hyperkalemia in hospitalized patients and associated outcomes. Data from a county ho...

Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients.
https://doi.org/10.1007/s11154-021-09677-7 10.1016/j.kint.2019.09.018 10.1001/archinternmed.2009.132 10.1093/eurheartj/ehy100 10.1111/ajt.16502 10.1038/nrneph.2014.168 10.1097/MNH.0000000000000657 10.1056/NEJMoa1506027 10.1152/ajprenal.1998.274.5.F817 10.1152/ajprenal.1998.274.6.F1109 10.1152/ajprenal.1987.252.3.F387 10.1172/JCI115962 10.1152/ajprenal.00169.2004 10.1152/ajprenal.00118.2006 10.1152/ajprenal.2000.279.1.F153 10.1046/j.1523-1755.2000.00970.x 10.1097/00007890-199610270-00025 10.21542/gcsp.2018.5 10.1038/nm.2497 10.1046/j.1399-0012.2003.00154.x 10.1210/endo.143.5.8821 10.1016/S0272-6386(12)70324-4 10.1002/lt.23440 10.7326/0003-4819-119-4-199308150-00008 10.7326/0003-4819-122-2-199501150-00004 10.5049/EBP.2007.5.2.111 10.1056/NEJM199303113281006 10.1155/2012/815907 10.1053/ajkd.2000.16220 10.1046/j.1365-2796.1996.43869000.x 10.1016/S0002-9343(89)80147-0 10.1128/AAC.02290-15 10.1378/chest.109.5.1250 10.1378/chest.105.2.417 10.1097/00007890-199210000-00010 10.1177/106002809102501102 10.1128/aac.32.10.1490 10.4103/0971-9784.203933 10.5005/jp/books/12382_8 10.1016/j.pcad.2020.02.002 10.1111/ajt.12119 10.1097/00007890-198903000-00032 10.7326/0003-4819-119-4-199308150-00007 10.7326/0003-4819-124-3-199602010-00006 10.7182/pit2015153 10.1186/s12879-019-3944-0 10.1111/j.1600-6143.2005.01079.x 10.1111/tid.12968 10.1111/tid.12769 10.1111/j.1399-3062.2011.00691.x 10.1111/j.1399-0012.2009.01129.x 10.1002/lt.500030207 10.1111/tid.12161 10.1093/cid/cit071 10.1164/rccm.2008-740ST 10.1097/00007890-199704150-00013 10.1016/S0140-6736(00)02480-6 10.1097/00007890-200101270-00019 10.1097/00007890-200109150-00007 10.1002/lt.21827 10.1097/TP.0000000000001524 10.1111/j.1600-6143.2010.03016.x 10.2215/CJN.05840710 10.1111/ajt.13322 10.1681/ASN.2013040435 10.2174/157340212804546062 10.3889/oamjms.2019.264 10.1038/ki.2009.377 10.1097/TP.0000000000001087 10.1681/ASN.2014080834 10.1007/s40620-017-0378-x 10.1007/s40265-020-01367-z 10.1093/ndt/gfz092 10.1161/01.HYP.33.3.862 10.1177/0897190014566306 10.1016/j.jash.2011.07.003 10.1159/000065225 10.1177/0897190007300728 10.1159/000355135 10.1053/j.ajkd.2016.12.017 10.1159/000511404 10.1113/jphysiol.1970.sp009056 10.1136/emj.19.1.92-a 10.1038/ki.1990.284 10.1016/S0272-6386(96)90460-6 10.1016/S0002-9343(88)80086-X 10.1159/000166827 10.1159/000064116 10.1053/j.ajkd.2006.01.014 10.1056/NEJM196101192640303 10.1097/SMJ.0b013e31819e8978 10.1097/00000478-199701000-00007 10.1097/TXD.0000000000001037 10.1111/ctr.13791 10.1111/ctr.13587
Reviews in Endocrine & Metabolic Disorders; Rizk JG, Lazo JG et. al.

Jul 23rd, 2021 - Hyperkalemia is a common and potentially life-threatening complication following kidney transplantation that can be caused by a composite of factors such as medications, delayed graft function, and possibly potassium intake. Managing hyperkalemia ...

Association of Dyskalemias with Ischemic Stroke in Advanced Chronic Kidney Disease Pati...
https://doi.org/10.1159/000516902
American Journal of Nephrology; Dashputre AA, Sumida K et. al.

Jul 22nd, 2021 - Hypo- and hyperkalemia are associated with a higher risk of ischemic stroke. However, this association has not been examined in an advanced chronic kidney disease (CKD) population. From among 102,477 US veterans transitioning to dialysis between 2...

see more →

Guidelines  1 results

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood...
https://doi.org/10.1016/j.cjca.2016.02.066
The Canadian Journal of Cardiology; Leung AA, Nerenberg K et. al.

Apr 28th, 2016 - Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, and treatment of hypertension. This year, we present 4 ne...

see more →

Drugs  146 results see all →

Clinicaltrials.gov  31 results

Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer
https://clinicaltrials.gov/ct2/show/NCT03229265

Apr 13th, 2020 - This is an open-label single center pharmacokinetic study of kidney transplant recipients with hyperkalemia receiving tacrolimus and MMF-based immunosuppression. Subjects will be screened for inclusion and exclusion criteria during the screening v...

A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.
https://clinicaltrials.gov/ct2/show/NCT03303521

Feb 20th, 2020 - The purpose of this study is to evaluate the efficacy of ZS in the treatment of hyperkalemia in patients on hemodialysis.

A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8
https://clinicaltrials.gov/ct2/show/NCT03337477

Jan 28th, 2020 - The study is designed to determine if ZS 10g administered up to three times over 10h added to insulin and glucose in patients presenting with hyperkalemia will prove tolerable and efficacious. Patients will receive ZS or Placebo on top of standard...

Improving Chronic Disease Management With Pieces
https://clinicaltrials.gov/ct2/show/NCT02587936

Oct 11th, 2019 - ICD-Pieces is a randomized, pragmatic clinical trial in four large healthcare systems to improve care of patients with coexistent chronic kidney disease, diabetes and hypertension. The investigators hypothesis is that patients who receive care wit...

Adrenal Artery Ablation Treats Primary Aldosteronism
https://clinicaltrials.gov/ct2/show/NCT03398785

Jul 8th, 2019 - Primary aldosteronism (PA) is one of the most common cause of endocrine and resistant hypertension. Current studies have shown that the activation of the renin-angiotensin-aldosterone system (RAAS) and the increased sympathetic nerve activity in t...

see more →

News  244 results

Fast Five Quiz: Hyperkalemia Management
https://reference.medscape.com/viewarticle/948621

Apr 9th, 2021 - Hyperkalemia is a clinically important acute electrolyte abnormality that can result in significant morbidity and life-threatening cardiac arrhythmias. Although uncommon in the general population, hyperkalemia is much more prevalent in patients wi...

Dapagliflozin Halves Hyperkalemia in Some HF Patients
https://www.medscape.com/viewarticle/940012

Oct 29th, 2020 - For patients with heart failure with reduced ejection fraction (HFrEF), the addition of dapagliflozin (Farxiga) to a mineralocorticoid receptor antagonist (MRA) halved the incidence of moderate to severe hyperkalemia, a prespecified analysis of DA...

Dapagliflozin Halves Hyperkalemia in Some HF Patients
https://www.staging.medscape.com/viewarticle/940012

Oct 29th, 2020 - For patients with heart failure with reduced ejection fraction (HFrEF), the addition of dapagliflozin (Farxiga) to a mineralocorticoid receptor antagonist (MRA) halved the incidence of moderate to severe hyperkalemia, a prespecified analysis of DA...

Study Supports Citrate Over Heparin Anticoagulation for Continuous Dialysis
https://www.medscape.com/viewarticle/939781

Oct 27th, 2020 - NEW YORK (Reuters Health) - A large randomized controlled trial supports the use of regional citrate over heparin anticoagulation to help prevent blood clot formation at the filter in patients receiving continuous dialysis therapies. Dialysis filt...

Novel Drug Slows Progression of Diabetic Kidney Disease
https://www.medscape.com/viewarticle/939724

Oct 23rd, 2020 - For patients with diabetic kidney disease, finerenone, an agent from a new class of selective, nonsteroidal mineralocorticoid receptor antagonists, led to significant reductions in combined adverse renal outcomes and in combined adverse cardiovasc...

see more →